Susan L Tucker

Author PubWeight™ 139.34‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2007 6.98
2 Cyclin E and survival in patients with breast cancer. N Engl J Med 2002 6.44
3 Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010 3.83
4 Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys 2004 3.21
5 Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2005 3.19
6 Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 2006 2.82
7 Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 2009 2.75
8 Prescribing radiation dose to lung cancer patients based on personalized toxicity estimates. J Thorac Oncol 2012 2.61
9 Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2007 2.28
10 Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 2003 2.19
11 Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol 2008 2.17
12 Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 2003 2.11
13 Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 2005 2.09
14 Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 2004 2.02
15 Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009 2.01
16 Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004 1.94
17 Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006 1.84
18 Mortality risk from squamous cell skin cancer. J Clin Oncol 2005 1.74
19 Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys 2007 1.74
20 Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004 1.70
21 Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys 2010 1.67
22 Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2005 1.63
23 Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol 2009 1.59
24 Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 2005 1.53
25 Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2002 1.51
26 T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys 2004 1.51
27 Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2010 1.49
28 Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys 2003 1.45
29 Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy. Radiother Oncol 2008 1.40
30 Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys 2011 1.37
31 International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer 2002 1.36
32 Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 2005 1.33
33 Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 2007 1.32
34 Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 2008 1.32
35 American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol 2012 1.29
36 Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. Int J Radiat Oncol Biol Phys 2005 1.29
37 Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004 1.25
38 Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 2002 1.20
39 African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy. Cancer 2006 1.20
40 Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 2005 1.20
41 Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007 1.17
42 Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2007 1.17
43 Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. Int J Cancer 2002 1.16
44 Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 2012 1.16
45 Osteoradionecrosis and radiation dose to the mandible in patients with oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2012 1.13
46 Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003 1.12
47 Characterization of rectal normal tissue complication probability after high-dose external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004 1.11
48 Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2006 1.09
49 Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 2002 1.07
50 Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys 2008 1.07
51 Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle 2009 1.06
52 The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome. Int J Radiat Oncol Biol Phys 2006 1.04
53 Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys 2003 1.04
54 Correlation of gross tumor volume excursion with potential benefits of respiratory gating. Int J Radiat Oncol Biol Phys 2004 1.04
55 Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006 1.04
56 The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oncol Biol Phys 2003 1.03
57 Staging of breast cancer in the neoadjuvant setting. Cancer Res 2008 1.03
58 Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011 1.02
59 Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res 2010 1.01
60 Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2005 1.00
61 Quantification of prostate and seminal vesicle interfraction variation during IMRT. Int J Radiat Oncol Biol Phys 2008 0.99
62 Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2013 0.99
63 Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys 2013 0.99
64 Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg 2013 0.97
65 Paget's disease of the breast: there is a role for breast-conserving therapy. Ann Surg Oncol 2005 0.95
66 Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat Med 2003 0.94
67 Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 2005 0.93
68 Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys 2007 0.93
69 Use of 4-dimensional computed tomography-based ventilation imaging to correlate lung dose and function with clinical outcomes. Int J Radiat Oncol Biol Phys 2013 0.93
70 Coexpression of alpha6beta4 integrin and guanine nucleotide exchange factor Net1 identifies node-positive breast cancer patients at high risk for distant metastasis. Cancer Epidemiol Biomarkers Prev 2009 0.93
71 An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer 2002 0.92
72 Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 2004 0.91
73 Dose-response for biochemical control among high-risk prostate cancer patients after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2003 0.91
74 Influence of preoperative radiation field on postoperative leak rates in esophageal cancer patients after trimodality therapy. J Thorac Oncol 2014 0.90
75 Statistical assessment of proton treatment plans under setup and range uncertainties. Int J Radiat Oncol Biol Phys 2013 0.90
76 Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012 0.89
77 Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2005 0.89
78 A technique to use CT images for in vivo detection and quantification of the spatial distribution of radiation-induced esophagitis. J Appl Clin Med Phys 2013 0.87
79 Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle 2012 0.86
80 Prospective analysis of carotid artery flow in breast cancer patients treated with supraclavicular irradiation 8 or more years previously: no increase in ipsilateral carotid stenosis after radiation noted. Cancer 2008 0.85
81 Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol 2008 0.85
82 Dosimetric benefits of respiratory gating: a preliminary study. J Appl Clin Med Phys 2004 0.84
83 A volumetric trend analysis of the prostate and seminal vesicles during a course of intensity-modulated radiation therapy. Am J Clin Oncol 2010 0.84
84 Is a 3-mm intrafractional margin sufficient for daily image-guided intensity-modulated radiation therapy of prostate cancer? Radiother Oncol 2007 0.83
85 First-year PSA kinetics and minima after prostate cancer radiotherapy are predictive of overall survival. Int J Radiat Oncol Biol Phys 2006 0.82
86 The delivery of IMRT with a single physical modulator for multiple fields: a feasibility study for paranasal sinus cancer. Int J Radiat Oncol Biol Phys 2004 0.82
87 Changes in the pelvic anatomy after an IMRT treatment fraction of prostate cancer. Int J Radiat Oncol Biol Phys 2007 0.82
88 Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy. Clin Cancer Res 2007 0.81
89 Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair. Clin Cancer Res 2003 0.81
90 Stage III follicular lymphoma: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 2003 0.80
91 Cluster models of dose-volume effects. Int J Radiat Oncol Biol Phys 2004 0.79
92 Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol 2011 0.79
93 Urethral pain among prostate cancer survivors 1 to 14 years after radiation therapy. Int J Radiat Oncol Biol Phys 2013 0.79
94 Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiation. Neuro Oncol 2013 0.79
95 Breast cancer patients with 10 or more involved axillary lymph nodes treated by multimodality therapy: influence of clinical presentation on outcome. Int J Radiat Oncol Biol Phys 2007 0.79
96 TGFβ1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy. PLoS One 2013 0.78
97 A novel method to incorporate the spatial location of the lung dose distribution into predictive radiation pneumonitis modeling. Int J Radiat Oncol Biol Phys 2011 0.78
98 Dosimetric uncertainties of three-dimensional dose reconstruction from two-dimensional data in a multi-institutional study. J Appl Clin Med Phys 2004 0.78
99 A method to estimate composite doses for organs at risk in prostate cancer patients treated with EBRT in combination with HDR BT. Acta Oncol 2014 0.78
100 Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg 2016 0.77
101 Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys 2003 0.77
102 Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study. Int J Radiat Oncol Biol Phys 2003 0.76
103 Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer 2011 0.76
104 Modulation of rodent spinal cord radiation tolerance by administration of platelet-derived growth factor. Int J Radiat Oncol Biol Phys 2004 0.76
105 Investigation of the relationship between gross tumor volume location and pneumonitis rates using a large clinical database of non-small-cell lung cancer patients. Int J Radiat Oncol Biol Phys 2011 0.75
106 Balancing radiation pneumonitis versus locoregional tumor control in non-small-cell lung cancer. J Thorac Oncol 2013 0.75
107 Daily bone alignment with limited repeat CT correction rivals daily ultrasound alignment for prostate radiotherapy. Int J Radiat Oncol Biol Phys 2008 0.75
108 Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma. Cancer 2002 0.75
109 Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer. Cancer 2010 0.75
110 Application of the electron pencil beam redefinition algorithm to electron arc therapy. Med Phys 2006 0.75
111 Learning anatomy changes from patient populations to create artificial CT images for voxel-level validation of deformable image registration. J Appl Clin Med Phys 2016 0.75
112 Nasopharyngeal cancer in the Middle East: experience of the American University of Beirut Medical Center. Int J Radiat Oncol Biol Phys 2005 0.75
113 Molecular response of follicular lymphoma to cyclophosphamide, doxorubicin, vincristine, prednisone C(H)OP or COP-based therapy as measured by polymerase chain reaction evidence of translocation (14;18)(q32;q21). Cancer J 2004 0.75
114 A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. Int J Radiat Oncol Biol Phys 2005 0.75